 |
|
 |
 |

Home > Company Index > Drugs > Diagnostic Substances > ID Biomedical Corporation
 |
ID Biomedical Corporation |
 |
 |
 |
PROFILE |
 |
ID Biomedical Corporation is out to identify rogue genes. Focusing on commercializing its vaccines and FDA-approved, gene-based Velogene assay, the biotechnology firm has developed cycling probe technology (CPT), which helps hospital labs quickly identify specific genes to diagnose various staphylococcus strains, TB, and other infectious diseases. ID Biomedical is developing CPT through alliances with companies such as Applied Biosystems and Third Wave Technologies. The company has under development vaccines for TB (with Aventis Pasteur), group A streptococcus, and HIV/AIDS. Assay maker Alexon-Trend has a license to produce and market Velogene worldwide, except in Japan where Mitsubishi Chemical will distribute it.
COMPETITION |
 |
Enzo Biochem, Inc. (ENZ)
Genome Therapeutics Corp. (GENE)
Myriad Genetics, Inc. (MYGN)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 8.10
1-Yr. Sales Growth: 3,950.0%
Employees: 28
Revenue per employee: $289,285.71
KEY PEOPLE |
 |
Anthony F. Holler
CEO
Dawn Caiarelli
CFO
CONTACT INFO |
 |
1510 - 800 W. Pender
Vancouver British Columbia V6C 2V6, Canada
Phone: 1-604-431-9314
Fax: 1-604-431-9378
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |